Todd Bazemore

Insider profile

Currently holds positions in KALA BIO Inc and Santhera Pharmaceuticals Holding AG

Performance

Overall performance
2.3

Performance over holding periods
4.2
30 days 90 days 120 days
Average return 47% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
4 75% Buy
34 71% Buy
47 69% Buy

Performance for realised trades
4.4
Average return -100%
Success rate 73%
Average holding period 220
Transactions 28

Positions

Position Company Period
Chief Operating Officer KALA BIO Inc Nov. 20, 2017 -
Chief Operating Officer Santhera U.S., Member of the Executive Management Board Santhera Pharmaceuticals Holding AG Sept. 6, 2016 -
Executive Vice President and Chief Commercial Officer Dyax Corp April 16, 2014 - Jan. 22, 2016

Todd Bazemore's trades of KALA BIO Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Sale
Price
70.54
Quantity 58,815 -48.3%
Value US$71,636
Transaction date
Proposed sale
Price
381.11
Quantity 79,133
Value US$1,371,818
Transaction date
Planned sale
Price
464.82
Quantity 13,492 +3.9%
Value US$4,390,734
Transaction date
Proposed sale
Price
4.01
Quantity 4,058
Value US$16,273
Transaction date
Planned sale
Price
3.74
Quantity 3,390 -3.7%
Value US$12,679
Transaction date
Planned sale
Price
4.75
Quantity 4,653 -5.3%
Value US$22,102
Transaction date
Proposed sale
Price
4.90
Quantity 4,356
Value US$21,342
Transaction date
Planned sale
Price
6.09
Quantity 2,093 -2.3%
Value US$12,746
Transaction date
Planned sale
Price
28.54
Quantity 62 -0.4%
Value US$1,769
Transaction date
Planned sale
Price
6.51
Quantity 214 -9.3%
Value US$1,393
Transaction date
Planned sale
Price
0.37
Quantity 3,092 -2.6%
Value US$1,144
Transaction date
Planned sale
Price
1.30
Quantity 3,454 -2.8%
Value US$4,490
Transaction date
Planned sale
Price
1.80
Quantity 12,544 -9.3%
Value US$22,579
Transaction date
Purchase
Price
7.60
Quantity 40 +2000.0%
Value US$304
Transaction date
Purchase
Price
13.39
Quantity 2 +inf%
Value US$27
Transaction date
Purchase
Price
5.75
Quantity 10,000 +inf%
Value US$57,500
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2025-10-24 2025-10-22 S Sale
58,815 -48.3%
70.54
US$71,636
58,815 -48.3% 70.54 US$71,636
2025-10-22 2025-10-22 PrS Proposed sale
79,133
381.11
US$1,371,818
79,133 381.11 US$1,371,818
2025-06-26 2025-06-24 PlS Planned sale
13,492 +3.9%
464.82
US$4,390,734
13,492 +3.9% 464.82 US$4,390,734
2025-06-24 2025-06-24 PrS Proposed sale
4,058
4.01
US$16,273
4,058 4.01 US$16,273
2025-06-04 2025-06-03 PlS Planned sale
3,390 -3.7%
3.74
US$12,679
3,390 -3.7% 3.74 US$12,679
2024-06-27 2024-06-26 PlS Planned sale
4,653 -5.3%
4.75
US$22,102
4,653 -5.3% 4.75 US$22,102
2024-06-24 2024-06-24 PrS Proposed sale
4,356
4.90
US$21,342
4,356 4.90 US$21,342
2024-06-03 2024-05-31 PlS Planned sale
2,093 -2.3%
6.09
US$12,746
2,093 -2.3% 6.09 US$12,746
2023-01-06 2023-01-04 PlS Planned sale
62 -0.4%
28.54
US$1,769
62 -0.4% 28.54 US$1,769
2022-10-28 2022-10-26 PlS Planned sale
214 -9.3%
6.51
US$1,393
214 -9.3% 6.51 US$1,393
2022-06-29 2022-06-27 PlS Planned sale
3,092 -2.6%
0.37
US$1,144
3,092 -2.6% 0.37 US$1,144
2022-01-05 2022-01-04 PlS Planned sale
3,454 -2.8%
1.30
US$4,490
3,454 -2.8% 1.30 US$4,490
2021-10-28 2021-10-26 PlS Planned sale
12,544 -9.3%
1.80
US$22,579
12,544 -9.3% 1.80 US$22,579
2020-10-28 2020-10-22 B Purchase
40 +2000.0%
7.60
US$304
40 +2000.0% 7.60 US$304
2020-10-28 2020-06-05 B Purchase
2 +inf%
13.39
US$27
2 +inf% 13.39 US$27
2020-03-17 2020-03-16 B Purchase
10,000 +inf%
5.75
US$57,500
10,000 +inf% 5.75 US$57,500